BR0304660A - Anticorpos direcionados a fator de tecido como anticoagulantes - Google Patents

Anticorpos direcionados a fator de tecido como anticoagulantes

Info

Publication number
BR0304660A
BR0304660A BR0304660-5A BR0304660A BR0304660A BR 0304660 A BR0304660 A BR 0304660A BR 0304660 A BR0304660 A BR 0304660A BR 0304660 A BR0304660 A BR 0304660A
Authority
BR
Brazil
Prior art keywords
antibodies
tissue factor
anticoagulants
factor
targeted antibodies
Prior art date
Application number
BR0304660-5A
Other languages
English (en)
Portuguese (pt)
Inventor
David Light
Kirk Mclean
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29401364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0304660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0304660A publication Critical patent/BR0304660A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/7455—Thrombomodulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR0304660-5A 2002-05-01 2003-04-30 Anticorpos direcionados a fator de tecido como anticoagulantes BR0304660A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37656602P 2002-05-01 2002-05-01
PCT/US2003/013521 WO2003093422A2 (en) 2002-05-01 2003-04-30 Novel tissue factor targeted antibodies as anticoagulants

Publications (1)

Publication Number Publication Date
BR0304660A true BR0304660A (pt) 2005-06-07

Family

ID=29401364

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0304659-1A BR0304659A (pt) 2002-05-01 2003-04-30 Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes
BR0304660-5A BR0304660A (pt) 2002-05-01 2003-04-30 Anticorpos direcionados a fator de tecido como anticoagulantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR0304659-1A BR0304659A (pt) 2002-05-01 2003-04-30 Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes

Country Status (29)

Country Link
US (3) US7250168B2 (enExample)
EP (2) EP1503785B1 (enExample)
JP (2) JP4567437B2 (enExample)
KR (2) KR101013697B1 (enExample)
CN (2) CN100563709C (enExample)
AR (1) AR039515A1 (enExample)
AT (2) ATE427121T1 (enExample)
AU (2) AU2003225255B2 (enExample)
BR (2) BR0304659A (enExample)
CA (2) CA2483909A1 (enExample)
CR (1) CR7584A (enExample)
DE (2) DE60326970D1 (enExample)
DK (2) DK1549341T3 (enExample)
EC (2) ECSP045467A (enExample)
ES (2) ES2354419T3 (enExample)
HK (1) HK1080372A1 (enExample)
IL (3) IL164733A0 (enExample)
MX (2) MXPA04010795A (enExample)
NO (2) NO20035848L (enExample)
NZ (2) NZ536243A (enExample)
PE (1) PE20040597A1 (enExample)
PL (2) PL210582B1 (enExample)
PT (2) PT1549341E (enExample)
RS (2) RS102404A (enExample)
RU (2) RU2345789C2 (enExample)
TW (1) TWI343388B (enExample)
UA (2) UA81114C2 (enExample)
WO (2) WO2003093422A2 (enExample)
ZA (2) ZA200409692B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2325316B8 (en) * 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
ES2254224T3 (es) * 1999-09-27 2006-06-16 Chugai Seiyaku Kabushiki Kaisha Nueva proteina del receptor de hematopoyetina, nr12.
EP2322648A1 (en) 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
JP4567437B2 (ja) * 2002-05-01 2010-10-20 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7425328B2 (en) 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7833978B2 (en) * 2004-02-20 2010-11-16 Emory University Thrombomodulin derivatives and conjugates
PT1745062E (pt) 2004-04-22 2014-07-11 Regado Biosciences Inc Moduladores melhorados de fatores de coagulação
US8252905B2 (en) 2005-06-03 2012-08-28 Mochida Pharmaceutical Co., Ltd. Anti-CD14 antibody fusion protein
WO2008039206A2 (en) * 2005-10-05 2008-04-03 The Trustees Of The University Of Pennsylvania Fusion proteins for inhibition and dissolution of coagulation
US20110040073A1 (en) * 2006-04-07 2011-02-17 Novo Nordisk Healthcare A/G Covalent Factor VII-Tissue Factor Complex
MY157796A (en) 2006-06-08 2016-07-29 Chugai Pharmaceutical Co Ltd Preventive or remedy for inflammatory disease
CA2665691A1 (en) * 2006-10-06 2008-04-17 Asahi Kasei Pharma Corporation Agent for therapy and/or improvement of disseminated intravascular coagulation
WO2008121814A1 (en) * 2007-03-28 2008-10-09 Ats Medical, Inc. Method for inhibiting platelet interaction with biomaterial surfaces
JP2010538667A (ja) * 2007-09-20 2010-12-16 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 新規オリゴクローナル抗体の製造方法
CN101939025B (zh) * 2007-12-05 2015-03-25 中外制药株式会社 搔痒症治疗药
US8333973B2 (en) * 2008-01-02 2012-12-18 The Trustees Of The University Of Pennsylvania Targeting recombinant therapeutics to circulating red blood cells
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AU2009282234A1 (en) * 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
WO2010045518A1 (en) * 2008-10-16 2010-04-22 The Trustees Of The University Of Pennsylvania Compositions containing thrombomodulin domains and uses thereof
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2230251A1 (en) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antibodies specifically active in the coronary plaque and method for their identification
CA2771328A1 (en) * 2009-08-28 2011-03-03 Bayer Healthcare Llc Cofactors for thrombin activation of factor vii and uses thereof
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
ES2676874T3 (es) 2010-06-04 2018-07-25 Tiumbio Co., Ltd. Proteína de fusión que tiene actividad del factor VII
RS56599B1 (sr) 2010-06-15 2018-02-28 Genmab As Konjugati humanog antitela sa lekom protiv tkivnog faktora
KR20130099027A (ko) * 2010-08-05 2013-09-05 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 혈전용해 및 응고억제 특성을 갖는 단백질 융합 구조물
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
WO2016167263A1 (ja) 2015-04-14 2016-10-20 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
JP5954916B1 (ja) 2015-04-14 2016-07-20 中外製薬株式会社 Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
WO2016176440A2 (en) * 2015-04-28 2016-11-03 Saint Louis University Thrombin-thrombomodulin fusion proteins as protein c activators
WO2017189943A1 (en) * 2016-04-28 2017-11-02 Saint Louis University Thrombin-thrombomodulin fusion proteins as a powerful anticoagulant
EP3541834A1 (en) * 2016-11-16 2019-09-25 Bayer Healthcare LLC Red blood cell targeted factor viii and method of using the same
BR102017005783A2 (pt) 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
CN112739716B (zh) 2018-05-07 2025-05-27 展马博联合股份有限公司 使用抗pd-1抗体与抗组织因子抗体-药物偶联物的组合治疗癌症的方法
JP2022513332A (ja) * 2018-10-04 2022-02-07 スロムボシス アンド コアグラシヨン アーべー プロテインｓレベルの決定方法
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
CN114686444B (zh) * 2020-12-31 2024-05-31 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用
CN114686443B (zh) * 2020-12-31 2023-11-03 广州万孚生物技术股份有限公司 杂交瘤细胞、抗血栓调节蛋白单克隆抗体及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5589173A (en) 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) * 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US4912207A (en) 1987-05-06 1990-03-27 Washington University DNA clone of human thrombomodulin and portions thereof
DK299087D0 (da) 1987-06-12 1987-06-12 Novo Industri As Proteins and derivatives thereof
US5298599A (en) 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
KR920701459A (ko) * 1989-02-17 1992-08-11 코돈 트롬보모듈린의 가용성 유사체
US5466668A (en) 1989-04-28 1995-11-14 Schering Aktiengesellschaft Superior thrombomodulin analogs for pharmaceutical use
US6063763A (en) 1989-04-28 2000-05-16 Schering Aktiengesellschaft Protease-resistant thrombomodulin analogs
US5256770A (en) 1990-04-09 1993-10-26 Schering Ag Oxidation resistant thrombomodulin analogs
KR930008093B1 (ko) 1990-08-03 1993-08-25 아사히가세이고오교 가부시끼가이샤 신규 폴리펩티드 및 이를 유효성분으로 하는 의약조성물
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5843442A (en) * 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
JPH0578397A (ja) * 1991-01-29 1993-03-30 Sumitomo Pharmaceut Co Ltd 血栓溶解タンパク質
JPH06133780A (ja) * 1992-10-23 1994-05-17 Sumitomo Pharmaceut Co Ltd 新規なｔ−ＰＡ改変体
US5916874A (en) 1994-04-20 1999-06-29 Asahi Kasei Kogyo Kabushiki Kaisha Method for treating liver injury
US5736364A (en) * 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
ATE512225T1 (de) * 1998-04-03 2011-06-15 Chugai Pharmaceutical Co Ltd Humanisierter antikörper gegen den menschlichen gewebefaktor (tf) und verfahren für die konstruktion eines solchen humanisierten antikörpers.
AU5081401A (en) * 2000-03-16 2001-10-03 Genentech Inc Anti-tissue factor antibodies with enhanced anticoagulant potency
US6632791B1 (en) 2000-06-21 2003-10-14 Schering Aktiengesellschaft Thrombomodulin analogs for pharmaceutical use
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AU2003201159A1 (en) 2002-01-08 2003-07-24 Bayer Healthcare Ag Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy
JP4567437B2 (ja) * 2002-05-01 2010-10-20 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗凝固剤としての新規組織因子標的化されたトロンボモジュリン融合タンパク質
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants

Also Published As

Publication number Publication date
AU2003225256B2 (en) 2009-06-04
IL164733A (en) 2011-05-31
KR20050045944A (ko) 2005-05-17
EP1549341B1 (en) 2009-04-01
RU2320366C2 (ru) 2008-03-27
CR7584A (es) 2006-05-30
NZ536242A (en) 2006-04-28
CN100412090C (zh) 2008-08-20
DE60334538D1 (de) 2010-11-25
WO2003093422A3 (en) 2004-07-15
CN1665526A (zh) 2005-09-07
RU2004135306A (ru) 2005-07-10
RU2004135308A (ru) 2005-08-10
US7622122B2 (en) 2009-11-24
EP1549341A2 (en) 2005-07-06
AU2003225256A1 (en) 2003-11-17
EP1503785B1 (en) 2010-10-13
US20080019985A1 (en) 2008-01-24
WO2003092602A2 (en) 2003-11-13
UA85996C2 (ru) 2009-03-25
EP1503785A2 (en) 2005-02-09
EP1549341A4 (en) 2006-10-18
TW200307043A (en) 2003-12-01
BR0304659A (pt) 2004-09-21
ES2354419T3 (es) 2011-03-14
JP2005532045A (ja) 2005-10-27
NO20035848L (no) 2004-02-27
PT1503785E (pt) 2011-01-17
KR101080587B1 (ko) 2011-11-04
IL164732A0 (en) 2005-12-18
ECSP045468A (es) 2005-01-28
PL210582B1 (pl) 2012-02-29
DK1503785T3 (da) 2011-02-07
US7622457B2 (en) 2009-11-24
ES2323056T3 (es) 2009-07-06
DE60326970D1 (de) 2009-05-14
MXPA04010795A (es) 2005-03-07
NO20035849L (no) 2004-02-27
PE20040597A1 (es) 2004-10-06
IL164733A0 (en) 2005-12-18
RS104504A (sr) 2007-02-05
US20040063632A1 (en) 2004-04-01
NZ536243A (en) 2006-06-30
CN1665534A (zh) 2005-09-07
US20080020965A1 (en) 2008-01-24
ECSP045467A (es) 2005-01-28
RS102404A (sr) 2006-12-15
ZA200409694B (en) 2006-02-22
WO2003092602A3 (en) 2004-08-26
ATE484524T1 (de) 2010-10-15
ZA200409692B (en) 2006-07-26
CN100563709C (zh) 2009-12-02
CA2483909A1 (en) 2003-11-13
ATE427121T1 (de) 2009-04-15
JP4567437B2 (ja) 2010-10-20
JP4460443B2 (ja) 2010-05-12
PL373960A1 (en) 2005-09-19
KR20050045945A (ko) 2005-05-17
TWI343388B (en) 2011-06-11
JP2005538046A (ja) 2005-12-15
AU2003225255A1 (en) 2003-11-17
HK1080372A1 (zh) 2006-04-28
CA2483910A1 (en) 2003-11-13
MXPA04010851A (es) 2005-02-14
RU2345789C2 (ru) 2009-02-10
PL373945A1 (en) 2005-09-19
US7250168B2 (en) 2007-07-31
PT1549341E (pt) 2009-05-29
KR101013697B1 (ko) 2011-02-10
WO2003093422A2 (en) 2003-11-13
UA81114C2 (en) 2007-12-10
EP1503785A4 (en) 2007-02-14
DK1549341T3 (da) 2009-07-06
AU2003225255B2 (en) 2008-07-31
AR039515A1 (es) 2005-02-23

Similar Documents

Publication Publication Date Title
BR0304660A (pt) Anticorpos direcionados a fator de tecido como anticoagulantes
ATE540976T1 (de) Antikörper zur inhibierung der blutgerinnung und verfahren zur deren verwendung
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
WO2003037911A3 (en) Antibodies for inhibiting blood coagulation and methods of use thereof
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
HUP0303915A2 (hu) Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációkra
BRPI0518565A2 (pt) composiÇÕes cardiovasculares
ES2188202T3 (es) Metodos de tratamiento para el cancer usando conjugados terapeuticos que se enlazan con aminofosfolipidos.
PT1383731E (pt) Compostos de biarilo como inibidores de serina-protease
WO2009017863A3 (en) Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
CR10627A (es) Metodos terapeuticos para el tratamiento de trastornos oculares vasculares con antagonistas de dii4
DE602007009408D1 (de) Ausführungen von ballonnähten
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
NO20070996L (no) Fremgangsmate for behandling av CCR2 medierte sykdommer eller lidelser
DE59910216D1 (de) Deckenelement für eine zusammengesetzte decke
ATE289319T1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
FR2838369B1 (fr) Procede de traitement de matieres lignocellulosiques, notamment du bois ainsi qu'un materiau obtenu par ce procede
ATE298387T1 (de) Bewehrungsbügel für mauerwerk, sowie damit hergestelltes mauerwerk
BR0313030A (pt) Agente resistente à sujeira e método de tratamento de substratos fibrosos para resistência à sujeira
ATE498305T1 (de) Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen
BRPI0411353A (pt) moléculas de corina modificadas tendo seqüências de ativação substitutas e aplicações das mesmas
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
CR7589A (es) Nuevos anticuerpos dirigidos contra factores tisulares como anticoagulantes
JP2003286300A5 (enExample)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.